Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Five years of lecanemab treatment keeps Alzheimer's at bay longer. New long-term data from the Clarity AD trial show that patients on continuous lecanemab had meaningfully slower disease progression compared to natural history cohorts — with the gap widening over time. Patients who started treatment with lower tau burden fared especially well, with most showing no decline or even improvement across key clinical measures.
Long-term data from the Clarity AD trial, presented at the CTAD 2026 conference, offer the most compelling evidence yet that lecanemab (Leqembi) can meaningfully slow Alzheimer's disease progression over an extended period. Among 351 patients who received 5 continuous years of treatment, CDR-SB scores — a key measure of cognitive and functional decline — diverged increasingly from external natural history cohorts over time, suggesting the drug's benefits grow rather than plateau.
Patients who entered treatment with lower baseline tau burden showed particularly notable outcomes: 66% experienced no decline or actual improvement on the CDR-SB at year 5, and similar trends held across cognitive and daily functioning assessments. Safety remained consistent with earlier findings, with the most common side effect (brain swelling/ARIA-E) concentrated in year 1 and tapering sharply thereafter.
By the Numbers:
Why it matters: These 5-year results strengthen the case for early, sustained lecanemab treatment in Alzheimer's — showing that clinical benefit doesn't just hold, it grows. For clinicians, the data also hint that identifying low-tau patients early could help predict who benefits most.